Beyond Air (NASDAQ:XAIR) Releases Earnings Results, Misses Estimates By $0.20 EPS

Beyond Air (NASDAQ:XAIR) issued its earnings results on Friday. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.20), Zacks reports. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.30 million. Beyond Air had a negative return on equity of 268.82% and a negative net margin of 447.75%.

Here are the key takeaways from Beyond Air’s conference call:

• Beyond Air said fiscal 2026 revenue rose 107% year over year to $7.7 million, with customer renewal rates of about 90%, signaling stronger adoption and retention for LungFit PH.
• The company reported a meaningful improvement in profitability metrics, including a $2 million swing to gross profit and a 35% improvement in operating results, helped by lower R&D and SG&A expenses.
• Management highlighted progress on the Gen 2 LungFit system, saying the FDA review remains on track and that potential approval could come in the second half of calendar 2026, with launch preparation underway for late 2026.
• The company expanded market access through a new national purchasing agreement with a top-three U.S. GPO, bringing its total to three major GPO relationships and broadening access to a substantial share of U.S. hospitals.
• Beyond Air issued first-time guidance of $8 million for calendar 2026 and $16 million-$18 million for calendar 2027, but the outlook assumes Gen 2 approval and commercialization in 2027 and still depends on FDA timing.

Beyond Air Stock Performance

Beyond Air stock opened at $0.49 on Friday. The firm has a market capitalization of $6.53 million, a PE ratio of -0.09 and a beta of 0.26. Beyond Air has a 1-year low of $0.33 and a 1-year high of $4.78. The firm’s 50 day simple moving average is $0.46 and its 200 day simple moving average is $0.81. The company has a current ratio of 5.12, a quick ratio of 4.77 and a debt-to-equity ratio of 2.65.

Institutional Trading of Beyond Air

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in Beyond Air by 1.5% during the second quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock valued at $144,000 after purchasing an additional 12,598 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Beyond Air during the 3rd quarter worth $1,753,000. Osaic Holdings Inc. grew its position in Beyond Air by 26.4% in the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after acquiring an additional 34,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Beyond Air in the third quarter worth $48,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Analyst Ratings Changes

XAIR has been the topic of a number of recent research reports. Wall Street Zen raised shares of Beyond Air to a “sell” rating in a research note on Saturday, March 7th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Beyond Air in a report on Friday, March 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Beyond Air in a research report on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Beyond Air presently has an average rating of “Hold” and an average price target of $10.00.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.